Literature DB >> 1850477

Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity.

J W Mandema1, L N Sansom, M C Dios-Vièitez, M Hollander-Jansen, M Danhof.   

Abstract

The relevance of EEG effect parameters as a measure of pharmacological effect intensity of benzodiazepines was evaluated. The concentration-EEG effect relationships of four benzodiazepine agonists, flunitrazepam, midazolam, oxazepam and clobazam, were quantified in individual rats and correlated with receptor affinity and anticonvulsant effect intensity of these compounds. Male Wistar-derived rats received a single i.v. dose of flunitrazepam (2.5 mg/kg), midazolam (5 mg/kg), oxazepam (10 mg/kg) and clobazam (20 mg/kg). Arterial blood samples were drawn frequently and EEG was monitored continuously until it had returned to preadministration levels. The concentrations of the benzodiazepines were determined by chromatographic means. Plasma protein binding was determined at 37 degrees C by ultrafiltration. The amplitudes in the 11.5 to 30 Hz frequency range, determined by aperiodic analysis, was used as EEG effect measure. Concentration-EEG effect relationships were derived by a pharmacokinetic-pharmacodynamic modeling procedure and characterized by the sigmoidal Emax model. The EC50 based on free drug concentrations (EC50,U, mean +/- S.E.) calculated for flunitrazepam (4.2 +/- 0.7 ng/ml) and midazolam (3.7 +/- 0.5 ng/ml) were similar and significantly less than the values for oxazepam (49 +/- 4 ng/ml) and clobazam (277 +/- 34 ng/ml) and illustrates the importance of using parameters referenced to unbound drug for comparative purposes. The maximal responses (Emax) for midazolam, oxazepam and clobazam were significantly less than for flunitrazepam suggesting that these three drugs may be regarded as partial agonists when compared to flunitrazepam. Receptor affinity was determined based on displacement of [3H] flumazenil in a washed brain homogenate at 37 degrees C.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1850477

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  23 in total

1.  Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats.

Authors:  A Cleton; D Mazee; R A Voskuyl; M Danhof
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  Mechanism-based modeling of functional adaptation upon chronic treatment with midazolam.

Authors:  A Cleton; J Odman; P H Van der Graaf; W Ghijsen; R Voskuyl; M Danhof
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

Review 3.  Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs.

Authors:  J W Mandema; M Danhof
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

4.  Development of a whole body physiologically based model to characterise the pharmacokinetics of benzodiazepines. 1: Estimation of rat tissue-plasma partition ratios.

Authors:  Ivelina Gueorguieva; Ivan A Nestorov; Susan Murby; Sophie Gisbert; Brent Collins; Kelly Dickens; Judith Duffy; Ziad Hussain; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-08       Impact factor: 2.745

5.  Relationship between drug plasma concentrations and psychomotor performance after single doses of ethanol and benzodiazepines.

Authors:  J Ingum; R Bjørklund; A Bjørneboe; A S Christophersen; E Dahlin; J Mørland
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography.

Authors:  Lia C Liefaard; Bart A Ploeger; Carla F M Molthoff; Ronald Boellaard; Adriaan A Lammertsma; Meindert Danhof; Rob A Voskuyl
Journal:  Mol Imaging Biol       Date:  2005 Nov-Dec       Impact factor: 3.488

Review 7.  Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm.

Authors:  D D Breimer; M Danhof
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

8.  A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat.

Authors:  L Aarons; J W Mandema; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

9.  Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship.

Authors:  J W Mandema; M T Kuck; M Danhof
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

10.  A comparison of the concentration-effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity.

Authors:  A L Van Steveninck; J W Mandema; B Tuk; J G Van Dijk; H C Schoemaker; M Danhof; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.